GEN Exclusives

More »

GEN News Highlights

More »
Oct 1, 2012

Novo Nordisk Drops Phase III Hemophilia Drug

  • Novo Nordisk has confirmed it will drop further development of the hemophilia therapy candidate vareptacog alfa, as a consequence of reports in August that some patients in a Phase IIIa trial had developed antibodies to the fast-acting recombinant factor VIIa analogue. The global adept 2 trial involved 72 hemophilia patients who had developed inhibitors to existing therapy, and was comparing treatment on demand using either vatreptacog alfa or NovoSeven®.

    Data from the study showed that while both drugs stopped a high percentage of bleeding episodes, a few patients developed anti-drug antibodies to vatreptacog alfa, including one patient with a potentially neutralizing effect in one sample. A number of patients developed cross-binding antibodies to NovoSeven, and although none were inhibitory, the development of anti-drug antibodies hadn’t previously been reported in patients treated with NovoSeven, including patients with inhibitors to factor VIII and IX. The fact that vareptacog alfa therapy did in some cases lead to the development of anti-NovoSeven antibodies has thus prompted Novo Nordisk to discontinue developing the candidate. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »